Provided by Tiger Fintech (Singapore) Pte. Ltd.

KALA BIO

1.49
+0.06004.20%
Post-market: 1.510.0200+1.34%19:35 EDT
Volume:248.25K
Turnover:361.62K
Market Cap:10.46M
PE:-0.22
High:1.49
Open:1.43
Low:1.42
Close:1.43
52wk High:20.60
52wk Low:1.10
Shares:7.02M
Float Shares:4.25M
Volume Ratio:0.30
T/O Rate:5.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.7074
EPS(LYR):-10.1450
ROE:-708.34%
ROA:-51.90%
PB:-3.26
PE(LYR):-0.15

Loading ...

Baker Bros. Advisors LP Reports Disposal of Kala Bio Inc. Common Shares

Reuters
·
Oct 03

Kala Bio Inc. Issues Correction to 8-K Report, Updates Disclosure on Workforce Reduction and Exit Activities

Reuters
·
Oct 03

BRIEF-Kala Bio Receives Notice Of Event Of Default From Oxford Finance Llc - SEC Filing

Reuters
·
Oct 01

KALA BIO Inc - on SEP 29, Receives Notice of Event of Default From Oxford Finance Llc - SEC Filing

THOMSON REUTERS
·
Oct 01

KALA BIO Inc - Total Obligations Declared Payable Is $29.1 Mln - SEC Filing

THOMSON REUTERS
·
Oct 01

Kala Bio Inc. Receives Default Notice from Oxford Finance; $29.1 Million Loan Accelerated Under Amended Loan Agreement

Reuters
·
Oct 01

KALA BIO Inc : Mizuho Cuts to Neutral From Outperform; Cuts Target Price to $1.5 From $30

THOMSON REUTERS
·
Sep 30

KALA BIO Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Sep 30

U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech

Reuters
·
Sep 30

KALA BIO Inc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
Sep 30

Kala Bio downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Sep 30

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Benzinga
·
Sep 30

Kala Pharmaceuticals downgraded to Market Perform at LifeSci Capital

TIPRANKS
·
Sep 29

Ladenburg Thalmann Downgrades KALA BIO to Neutral From Buy

MT Newswires Live
·
Sep 29

KALA BIO Shares Plunge 94% to $1.2 After Scrapping Development of Lead Drug

THOMSON REUTERS
·
Sep 29

Kala Pharmaceuticals trading halted, volatility trading pause

TIPRANKS
·
Sep 29

KALA BIO Shares Plunge 93.6% to $1.2 Premarket as Co Scraps Development of Eye Disease Drug After Trial Failure

THOMSON REUTERS
·
Sep 29

BRIEF-Kala Bio Approves 51% Workforce Reduction - SEC Filing

Reuters
·
Sep 29

Kala Bio to Stop Eye Defect Treatment Development After Study Misses Primary Endpoint

Dow Jones
·
Sep 29

BRIEF-Kala Bio Announces Topline Results From Chase Phase 2B Clinical Trial

Reuters
·
Sep 29